Claims for Patent: 12,110,298

Summary for Patent: 12,110,298

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Mathew M. Mulhern, Fredrik Lars NORDSTROM, Ahmad Y. Sheikh
Assignee:	AbbVie Inc
Application Number:	US18/369,272
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,110,298
Patent Claims:	1. A solid form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) comprising amorphous freebase or Freebase Hydrate Form C. 2. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises between about 0.8% and about 3.7% by weight water. 3. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises about 3.7% by weight water. 4. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises about 0.8% by weight water. 5. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises less than about 4% by weight water. 6. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises less than about 7% by weight water. 7. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises less than about 10% by weight water. 8. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase comprises less than 12% by weight water. 9. The solid form of claim 1, wherein the amorphous freebase has glass transition temperature onset at about 119° C. 10. The solid form of claim 1, wherein the amorphous freebase has glass transition temperature midpoint at about 122° C. 11. The solid form of claim 1, wherein the solid form is the amorphous freebase, and wherein the amorphous freebase reversibly sorbs up to 13% water at 90% relative humidity at 25° C. 12. A process for preparing a pharmaceutical tablet, comprising contacting an amorphous freebase solid form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) with a pharmaceutically acceptable carrier, wherein the amorphous freebase comprises less than about 13% by weight water. 13. The process of claim 12, wherein the amorphous freebase comprises less than about 10% by weight water. 14. The process of claim 13, wherein the amorphous freebase comprises less than about 7% by weight water. 15. The process of claim 14, wherein the amorphous freebase comprises less than about 4% by weight water. 16. The process of claim 15, wherein the amorphous freebase comprises about 3.7% by weight water. 17. The process of claim 15, wherein the amorphous freebase comprises about 0.8% by weight water. 18. The process of claim 15, wherein the amorphous freebase comprises between about 0.8% and about 3.7% by weight water. 19. The process of claim 12, wherein the amorphous freebase has a glass transition temperature midpoint at about 119° C. 20. The process of claim 12, wherein the amorphous freebase has a glass transition temperature midpoint at about 122° C. 21. The process of claim 12, wherein the amorphous freebase reversibly sorbs up to 13% water at 90% relative humidity at 25° C. 22. The solid form of claim 1, wherein the amorphous freebase is characterized by having an X-ray powder diffraction pattern substantially as shown in FIG. 2A. 23. The solid form of claim 1, wherein the amorphous freebase is characterized by having an X-ray powder diffraction pattern substantially as shown in FIG. 2B. 24. The solid form of claim 2, wherein the amorphous freebase is characterized by having an X-ray powder diffraction pattern substantially as shown in FIG. 2A. 25. The solid form of claim 2, wherein the amorphous freebase is characterized by having an X-ray powder diffraction pattern substantially as shown in FIG. 2B. 26. A pharmaceutical tablet comprising the solid form of claim 1 and a pharmaceutically acceptable carrier. 27. A pharmaceutical tablet comprising the solid form of claim 2 and a pharmaceutically acceptable carrier. 28. A pharmaceutical tablet comprising the solid form of claim 22 and a pharmaceutically acceptable carrier. 29. A pharmaceutical tablet comprising the solid form of claim 23 and a pharmaceutically acceptable carrier. 30. A pharmaceutical tablet comprising the solid form of claim 24 and a pharmaceutically acceptable carrier. 31. A pharmaceutical tablet comprising the solid form of claim 25 and a pharmaceutically acceptable carrier.